Sort
326,823 grants matching “clinical trial”
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
$2,203,403Robert M Califf · Duke University · UL1 · FY2006 · RR
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections- Small Clinical Trials Unit (SCTU)
$2,203,379Judith S. Currier · University Of California Los Angeles · UM1 · FY2025 · AI
SC COBRE for Translational Research Improving Musculoskeletal Health (SC-TRIMH)
$2,203,367Hai Yao · Clemson University · P20 · FY2019 · GM
Targeting Lung Cancer Vulnerabilities
$2,203,273John D Minna · Ut Southwestern Medical Center · P50 · FY2020 · CA
University of North Carolina - Chlamydia Vaccine Initiative (UNC-CVI)
$2,203,024Toni Darville · Univ Of North Carolina Chapel Hill · U19 · FY2020 · AI
Locomotor Experience Applied Post-Stroke (LEAPS)
$2,203,006Pamela W. Duncan · Duke University · R01 · FY2008 · NS
Molecular and Clinical Approaches to Colon Cancer Precursors
$2,202,724Randall Walter Burt · University Of Utah · P01 · FY2011 · CA
An oral vaccine against Chlamydia trachomatis
$2,202,675Guangming Zhong · University Of Texas Hlth Science Center · U01 · FY2024 · AI
Novel Adenovirus Vector-Based Vaccines for HIV-1
$2,202,559Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2008 · AI
PERU Clinical Trial Unit
$2,202,177Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2024 · AI
Irreversible Kidney Injury in Renovascular Hypertension
$2,202,168Juan C Romero · Mayo Clinic Rochester · P01 · FY2007 · HL
Trial to Reduce IDDM in the Genetically at Risk -study
$2,202,070Mikael Knip · University Of Helsinki · U01 · FY2011 · HD
Trial to Reduce IDDM in the Genetically at Risk -study
$2,201,930Mikael Knip · University Of Helsinki · U01 · FY2015 · HD
16/16 Action for Health in Diabetes Extension Study Biostatistics Research Center
$2,201,808Mark Andrew Espeland · Wake Forest University Health Sciences · U01 · FY2018 · DK
Alzheimer Disease Research Center
$2,201,559Helena Chang Chui · University Of Southern California · P50 · FY2018 · AG
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,201,443Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2021 · DA
Stem Cell Biology: New Directions in Clinical and Basic Research
$2,201,423Peter J Quesenberry · Rhode Island Hospital · P20 · FY2013 · GM
The ENRGISE Study
$2,201,275Marco Pahor · University Of Florida · U01 · FY2016 · AG
Botswana-Harvard School of Public Health AIDS Initiative Partnership CTU
$2,200,921Myron E Essex · Harvard School Of Public Health · UM1 · FY2013 · AI
The Alzheimer's Disease Research Center at the University of California, Irvine
$2,200,895Frank M Laferla · University Of California-Irvine · P50 · FY2019 · AG
SPORE in Lung Cancer
$2,200,821Paul A Bunn · University Of Colorado Denver · P50 · FY2006 · CA
Center for Research Improving Treatment of Drug Abuse
$2,200,704University Of Pennsylvania · P60 · FY2003 · DA
Tailored Non-Pharmacotherapy Services for Chronic Pain: Testing Scalable and Pragmatic Approaches
$2,200,655Lynn Larson Debar · Kaiser Foundation Research Institute · UH3 · FY2022 · AG
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ
$2,200,637Stephen H Tsang · Columbia University Health Sciences · R24 · FY2020 · EY
Integration of Whole Genome Sequencing into Clinical Medicine
$2,200,260Robert C. Green · Brigham And Women'S Hospital · U01 · FY2013 · HG